Laura Demayo Steele
Laura Demayo Steele was appointed President and General Manager (GM) of Eli Lilly and Company UK, Ireland & Northern Europe in July 2021. Laura leads Lilly’s commercial business operations in six countries, across the company’s current and emerging portfolio in Diabetes, Oncology, Immunology and Neuroscience. Laura joined the UK from her previous role in Lilly’s Corporate Business Development division in the US, where she specialised in innovation-led partnerships, large-scale projects in M&A, investments and joint ventures to drive growth across the company.
An insightful and authentic leader, Laura is a champion of diversity and inclusion initiatives and is passionate about developing talent and building high-performing teams. Laura’s 18-year career at Lilly spans sales, payer and marketing roles, where she built a reputation for a tenacious approach to innovation and her unfaltering commitment to patient-centricity. Under Laura’s leadership, the company’s Migraine Marketing division in Indianapolis accomplished multiple company and industry firsts, including projects in telemedicine and digital marketing. Laura was awarded the Gold Marketer, 2020 Marketer of the Year by Medical Marketing & Media. Laura has a Bachelor of Science in Business Administration (Villanova University), with a Major in Marketing and Minor in Communications.
Jyun Yan Yang
Jyun-Yan (Jeff) Yang is the Senior Medical Director for the Lilly Northern European Hub. Jeff has been with Lilly for more than 10 years and served as the medical director for the Taiwan affiliate, Asia Operations region and global Emgality team. Before coming to UK, Jeff was the Global Brand Development leader for the migraine platform, developing and commercialising novel migraine treatments around the world. Prior to Lilly, Jeff had over 15 years of experience in healthcare management consulting, pharmaceutical development and clinical medicine.
Jeff received his Doctor of Medicine degree from Kaohsiung Medical University in Taiwan. He earned a Master of Science degree in Health Policy and Management from Harvard School of Public Health and received the Charles F. Wilinsky Award for Academic Excellence. He recently co-authored manuscripts which were published in the journals of Cephalalgia, Headache, and New England Journal of Medicine.
Sue Forda is Vice President, International Regulatory Affairs, Eli Lilly and Company. She is responsible for all International regulatory aspects of Lilly’s portfolio for new and existing products. Sue is also Managing Director of the Eli Lilly UK Research and Development office.
Sue has contributed to trade association activities for many years and is a member of EFPIA’s Innovation Board Steering Committee and a member of EFPIA’s Regulatory Strategy Committee. She is also a member of the ICH management committee.
Sue trained as a pharmacist. After completing a PhD in neuropharmacology, she worked as a post-doctoral research fellow at the University of London.
PP-MG-GB-0275 September 2021